Compare MTG & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTG | INDV |
|---|---|---|
| Founded | 1957 | N/A |
| Country | United States | United States |
| Employees | 542 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 2008 | 2014 |
| Metric | MTG | INDV |
|---|---|---|
| Price | $26.36 | $36.31 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.50 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 2.0M |
| Earning Date | 04-29-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | 8.65 | ★ 8100.00 |
| EPS | ★ 0.76 | 0.69 |
| Revenue | $1,213,636,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | ★ $34.03 | $53.41 |
| Revenue Growth | 0.49 | ★ 4.29 |
| 52 Week Low | $25.23 | $11.08 |
| 52 Week High | $29.97 | $41.00 |
| Indicator | MTG | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 52.04 |
| Support Level | $25.78 | $34.91 |
| Resistance Level | $27.64 | $37.83 |
| Average True Range (ATR) | 0.66 | 1.51 |
| MACD | -0.14 | -0.30 |
| Stochastic Oscillator | 21.92 | 35.41 |
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).